Genmab — Marts 2015
-
ABG Sundal Collier optager dækning af Genmab med kursmålet 655
-
Solsen du skal tænke at hvis de rapporter data til ASCO phase I delen så skal de køre udvidelsesdelen phase II i nogle udvalgte indikationer osv. Så tror generelt først vi vil se opstart/annoncering omkring slut 2015 så det er først i 2016 udgifterne til TF-ADC vil begynde at rulle for real
-
Lige læst ABG Sundals analyse. Den er altså gennemarbejdet. +30 siders genmab analyse
-
ABG Sundal: Out de-risked SOTP is 1011 DKK per share
-
De estimerer J&J bruger over 1 mia. $ ÅRLIGT på at udvikle Daratumumab
-
ABG har ramt rigtigt før: http://www.business.dk/investor/genmababg-salgspotentiale-overvurderet-avis
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind